The addition of lapatinib to paclitaxel improves survival in patients with newly diagnosed HER2-positive metastatic breast cancer, further validating the importance of HER2 signalling as a target in this cancer subtype. However, the availability of other more-effective and less-toxic HER2-targeted therapies limits the clinical usefulness of the regimen.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
von Minckwitz, G. et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J. Clin. Oncol. 27, 1999–2006 (2009).
Geyer, C. E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733–2743 (2006).
Guan, Z. et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2011.40.5241.
Gelmon, K. A. et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2+ metastatic breast cancer: interim analysis of NCIC CTG MA.31/GSK EGF 108919 [abstract]. J. Clin. Oncol. 18 (Suppl.), LBA671 (2012).
Untch, M. et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 13, 135–144 (2012).
Baselga, J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379, 633–640 (2012).
Baselga, J. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109–119 (2012).
Hurvitz, S. A. et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 31, 1157–1163 (2013).
Lin, N. U. et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15, 1452–1459 (2009).
Acknowledgements
The author would like to thank Susan G. Komen For the Cure for financial support.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has received research funding from the following company: Genentech.
Rights and permissions
About this article
Cite this article
Krop, I. HER2-positive breast cancer—sifting through many good options. Nat Rev Clin Oncol 10, 312–313 (2013). https://doi.org/10.1038/nrclinonc.2013.72
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.72
